Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 6

Once-daily fosamprenavir with ritonavir in the treatment of HIV infection in therapy-naïve patients

Authors Leo Flamholc, Magnus Gisslén

Published 5 December 2008 Volume 2008:4(6) Pages 1281—1284

DOI https://doi.org/10.2147/TCRM.S3109

Review by Single-blind

Peer reviewer comments 4

Leo Flamholc1, Magnus Gisslén2

1Department of Infectious Diseases, Malmö University Hospital, Malmö, Sweden; 2Sahlgrenska University Hospital/Östra, Gothenburg, Sweden

Abstract: Treatment options for HIV patients have dramatically improved since the introduction of efficacious antiretroviral combination therapy more than a decade ago. Treatment regimens have been simplified with fewer pills and fewer daily dosages. Fosamprenavir is a protease inhibitor with a rather long half-life which makes it a candidate for once-daily use. Once-daily dosage of ritonavir-boosted fosamprenavir is approved in the US, but not in Europe, for treatment in patients without prior antiretroviral treatment. Here we review the background and rationale for once-daily dosage of ritonavir-boosted fosamprenavir. The rather limited studies that have been published so far indicate that fosamprenavir 1400 mg may be used once daily boosted with ritonavir. The optimal ritonavir dose to be given together with fosamprenavir is still to be defined, though available results indicate that a dose of 100 mg may be adequate provided that no protease inhibitor resistance is present.

Keywords: HIV, fosamprenavir, ritonavir

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Cationic star-shaped polymer as an siRNA carrier for reducing MMP-9 expression in skin fibroblast cells and promoting wound healing in diabetic rats

Li N, Luo HC, Yang C, Deng JJ, Ren M, Xie XY, Lin DZ, Yan L, Zhang LM

International Journal of Nanomedicine 2014, 9:3377-3387

Published Date: 15 July 2014

Dendrosomal curcumin nanoformulation downregulates pluripotency genes via miR-145 activation in U87MG glioblastoma cells

Tahmasebi Mirgani M, Isacchi B, Sadeghizadeh M, Marra F, Bilia AR, Mowla SJ, Najafi F, Babaei E

International Journal of Nanomedicine 2014, 9:403-417

Published Date: 13 January 2014

Silymarin-loaded solid nanoparticles provide excellent hepatic protection: physicochemical characterization and in vivo evaluation

Yang KY, Hwang DH, Yousaf AM, Kim DW, Shin YJ, Bae ON, Kim YI, Kim JO, Yong CS, Choi HG

International Journal of Nanomedicine 2013, 8:3333-3343

Published Date: 28 August 2013

Descemet-stripping automated endothelial keratoplasty for vitrectomized cases with traumatic aniridia and aphakic bullous keratopathy

Eguchi H, Miyamoto T, Hotta F, Tomida M, Inoue M, Mitamura Y

Clinical Ophthalmology 2012, 6:1513-1518

Published Date: 17 September 2012

Acoustic cardiac signals analysis: a Kalman filter–based approach

Salleh SH, Hussain HS, Swee TT, Ting CM, Noor AM, Pipatsart S, Ali J, Yupapin PP

International Journal of Nanomedicine 2012, 7:2873-2881

Published Date: 11 June 2012

Functionalization of single-walled carbon nanotubes and their binding to cancer cells

Madani SY, Tan A, Dwek M, Seifalian AM

International Journal of Nanomedicine 2012, 7:905-914

Published Date: 22 February 2012

Improved subjective symptoms of conjunctivochalasis using bipolar diathermy method for conjunctival shrinkage

Kashima T, Akiyama H, Miura F, Kishi S

Clinical Ophthalmology 2011, 5:1391-1396

Published Date: 23 September 2011

A review of the use of ketorolac tromethamine 0.4% in the treatment of post-surgical inflammation following cataract and refractive surgery

Helga P Sandoval, Luis E Fernández de Castro, David T Vroman, Kerry D Solomon

Clinical Ophthalmology 2007, 1:367-371

Published Date: 15 February 2008

Mirtazapine in the treatment of essential tremor: an open-label, observer-blind study

Davide Uccellini, G Grampa, I La Spina, D Nasuelli, I Neromante, L Politini, F Reverberi, D Porazzi, V Carli, G Camardese

Neuropsychiatric Disease and Treatment 2006, 2:95-100

Published Date: 15 March 2006